Screening for diabetic foot disease in community and outpatient settings successfully predicts those at risk of ulceration ([@B1]--[@B4]). Hospitalized individuals with diabetes are older, largely bed bound, have more comorbidities, and are at greater risk; screening these patients should be a priority so that foot protection can be targeted. It is disappointing that a recent audit of diabetes care in U.K. hospitals found fewer than one-third of patients had received a foot examination and 3% had developed a new foot lesion during their inpatient stay ([@B5]). Admitting doctors commonly cite not being able to find the necessary equipment as a barrier to screening. In community settings, the 10-g monofilament (MF) has gained acceptability as a simple, quick, and inexpensive method that detects a 7.7-fold increased ulceration risk ([@B2],[@B3],[@B6]). The MF has potential use in hospitals; however, its use would require training significant numbers of people as well as the initial purchase expense and recurrent expenditure to replace used filaments and lost devices. Furthermore, there is still the obstacle of having to find the device. In the absence of neurologic instruments, many physicians touch the feet with cotton wool or even with their fingers. We have taken this practice and formalized it into a simple, quick, and easily taught procedure that we have named the Ipswich Touch Test (IpTT). This study determines whether the IpTT has sufficient specificity and sensitivity for it to be recommended for inpatient screening when compared with the MF and vibration perception threshold (VPT).

RESEARCH DESIGN AND METHODS {#s5}
===========================

The study included 265 individuals with diabetes comprising inpatients and attendees at foot and general diabetes clinics. Amputees and those unable to comply were excluded. Four physicians, nine podiatrists, and five medical students undertook the examinations.

Test procedures {#s6}
---------------

The VPT was measured in both halluces using a neurothesiometer (Horwell Scientific, U.K.) following the established method of limits ([@B7]).

Pressure sensation was assessed using a 10-g MF (Neuropen, Owen Mumford, U.K.) applied for 1--2 s to the tips of the first, third, and fifth toes and to the dorsum of both halluces ([@B8]). MFs were changed at the recommended frequency and rested after 10 applications ([@B9]).

The IpTT involves lightly touching/resting the tip of the index finger for 1--2 s on the tips of the first, third, and fifth toes and the dorsum of the hallux. Two screening methods were assessed. Method A involved touching all of the above sites in both feet and defined neuropathy as ≥2 insensate of the 8 sites. Method B involved touching only the tips of the first, third, and fifth toes and defined neuropathy as ≥2 insensate of the 6 sites. Examiners were instructed not to push, prod, tap, or poke because this may elicit a sensation other than light touch. With eyes closed, subjects were instructed to say yes whenever they felt the touch.

Interoperator reproducibility of the IpTT was assessed by repeat testing in a subset of 26 subjects by another assessor who was blinded to the original findings.

Criterion standards {#s7}
-------------------

A VPT ≥25 V was the agreed gold standard because this is associated with an eightfold increased ulcer risk ([@B10]). We also directly compared the IpTT with the MF.

Statistical analysis {#s8}
--------------------

Sensitivity, specificity, and predictive values were calculated for the MF and IpTT against the VPT standard. Interoperator reproducibility was assessed using the κ statistic, as was concordance between the IpTT and MF, with a κ of 0.61--0.80 indicating substantial agreement and a κ of 0.81--1 indicating almost perfect agreement ([@B11]). Receiver operating characteristic curves were generated for eight- and six-site examinations of the MF and IpTT. Data were analyzed using SPSS 17.0 for Windows.

RESULTS {#s9}
=======

The mean age of the study subjects was 64.5 years; 79% had type 2 diabetes and 24% had a previous foot ulcer.

[Table 1](#T1){ref-type="table"} displays sensitivities, specificities, and predictive values for methods A and B. Direct comparison of the IpTT and MF showed almost perfect agreement, with discordance in only 20 of 265 individuals with method A (κ = 0.849, *P* \< 0.0001) and in only 16 of 265 individuals with method B (κ = 0.879, *P* \< 0.0001). Receiver operating characteristic areas under the curve for the MF and IpTT compared with the VPT were 0.87 and 0.84, respectively, for method A and 0.85 and 0.83, respectively, for method B.

###### 

Sensitivity, specificity, predictive values, and likelihood ratios for the MF and IpTT against a VPT ≥25 V as gold standard

                    Method A   Method B         
  ----------------- ---------- ---------- ----- ------
  Sensitivity (%)   85         79         81    76
  Specificity (%)   88         90         91    90
  PPV               89         90         91    89
  NPV               81         79         81    77
  LHR+              7.6        8.1        9.1   7.7
  LHR−              0.16       0.24       0.2   0.27

Method A uses 8 sites (tips of first, third, and fifth toes and dorsum of hallux) and a criterion of ≥2 out of 8 insensate sites to indicate at-risk feet. Method B uses 6 sites (tips of first, third, and fifth toes) and a criterion of ≥2 out of 6 insensate sites to indicate at-risk feet.

PPV, positive predictive value; NPV, negative predictive value; LHR+, positive likelihood ratio; LHR−, negative likelihood ratio.

The interoperator reproducibility represented by the κ statistic was 0.68 (*P* \< 0.001), indicating substantial agreement.

CONCLUSIONS {#s10}
===========

The IpTT was found to have a similar sensitivity, specificity, and operating characteristic as the MF when assessed against a VPT ≥25. Furthermore, when compared directly with the MF, the IpTT was found to have excellent concordance. The improvement in performance when eight rather than six sites were used was marginal and insignificant in clinical terms. Perhaps more meaningful, despite lacking the pressure precision of the MF, the IpTT used at six sites missed only 12 of the 147 patients diagnosed as at risk using the MF and gave only four false positives. We recommend using six rather than eight sites because the method is quicker and easier to teach and remember.

To ensure generalizability, the study was performed in three hospitals and by 18 different professionals. Although no nurses or care assistants participated, we see no reason why the method should not be transferrable.

The IpTT was devised out of a desire to prevent inpatient-acquired foot lesions through greater awareness of the need to protect the feet ([@B5],[@B12]). The procedure is simple, reliable, and quick; requires no special instruments; is easily sterilized by hand washing; and is always at hand. The IpTT necessitates little training and can be undertaken by those tasked with providing pressure relief---care assistants and nurses---giving them immediate feedback as to which patients require protection. We believe that once introduced into hospitals, this test should result in increased screening for at-risk feet and in more diabetic individuals' receiving appropriate pressure relief.

Although initially devised to be used with inpatients, the IpTT may have applications for community screening, particularly in areas where funding for testing equipment is limited.

No potential conflicts of interest relevant to this article were reported.

G.R. developed the concept, designed the study, and wrote the manuscript. P.R.V. designed the study, researched data, and wrote the manuscript. N.B., C.G.T., and C.G. researched data, contributed to discussion, and reviewed the manuscript. A.I.A. provided statistical advice, contributed to discussion, and reviewed the manuscript. M.D. researched data, contributed to discussion, and reviewed the manuscript.

Parts of this study were presented in abstract form at the 20th Annual Meeting of the Diabetic Neuropathy Study Group (NEURODIAB) of the European Association for the Study of Diabetes (EASD), Stockholm, Sweden, 17--19 September 2010.
